Xenon Pharmaceuticals Inc.

Operating margin

−4974.3%

Net margin

−4612.1%

Return on equity

−59.5%

Return on assets

−54.6%

Return on capital (ROCE)

−63.1%

Liabilities / assets

8.1%

Debt / equity

0.09×

Book value / share

$7.60

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

6.89safe

Accruals / assets

−10.5%clean

Piotroski F-Score

2/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Phase 2Active Not Recruitingreadout ~2021-09-02
  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
• Phase 3Recruitingreadout ~2026-08
  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
• Phase 3Recruitingreadout ~2026-10
  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
• Phase 3Enrolling By Invitationreadout ~2027-01
  An Open-Label Study of Azetukalner in Major Depressive Disorder
• Phase 3Recruitingreadout ~2027-04
  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
• Phase 3Recruitingreadout ~2027-05
  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
• Phase 3Recruitingreadout ~2028-06
  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
• Phase 3Enrolling By Invitationreadout ~2029-06
  An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

• Results of operations · Regulation FD disclosureMay 7, 2026
• Director / officer changeApr 13, 2026
• Other material eventMar 13, 2026
• Entered a material agreement · Other material eventMar 12, 2026
• Regulation FD disclosureMar 9, 2026
• Other material eventFeb 27, 2026
• Results of operations · Regulation FD disclosureFeb 26, 2026
• Director / officer changeDec 1, 2025

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.